Influence of particle size on lung deposition and pharmacokinetics of beclomethasone dipropionate in children

Pediatric Pulmonology

Volumn 35, Issue 3, 2003, Pages 192-199

  Agertoft, L ^a,c   Laulund, L W ^a   Harrison, L I ^b   Pedersen, S ^a  

^a KOLDING HOSPITAL   (Denmark)

^b 3M COMPANY   (United States)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

BDP; Children; Lung deposition; Pharmacokinetics

Indexed keywords

BECLOMETASONE; BECLOMETASONE 17 PROPIONATE; BECLOMETASONE 21 PROPIONATE; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CHARCOAL; DRUG METABOLITE; FLUORINATED HYDROCARBON; UNCLASSIFIED DRUG;

ADOLESCENT; AIRWAY DYNAMICS; ARTICLE; ASTHMA; CHILD; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; GASTROINTESTINAL ABSORPTION; HALF LIFE TIME; HUMAN; LUNG ALVEOLUS CELL; LUNG DEPOSITION; LUNG VOLUME; METERED DOSE INHALER; PARTICLE SIZE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE;

ADMINISTRATION, INHALATION; ADOLESCENT; AREA UNDER CURVE; BECLOMETHASONE; BIOLOGICAL AVAILABILITY; CHILD; CROSS-OVER STUDIES; FEMALE; HUMANS; LUNG; MALE; PARTICLE SIZE; RANDOMIZED CONTROLLED TRIALS;

EID: 0037371538     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/ppul.10238     Document Type: Article

References (24)

1. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998;12:1346-1353.
2. Agertoft L, Andersen A, Weibull E, Pedersen S. Systemic availability and pharmacokinetics of nebulized budesonide in preschool children with asthma. Arch Dis Child 1999;80:241-247.
3. Anhoej J, Thorsson L, Bisgaard H. The systemic exposure of budesonide inhaled from a metal spacer is similar in young children and adults. Eur Respir J 1998;12:378 [abstract].
4. Thorsson L. Studies on the deposition, bioavailability and systemic activity of glucocorticoids in man. Thesis, Department of Clinical Pharmacology, University of Lund, Sweden; 1998. p 1-73.
5. Borgström L. Methodological studies on lung deposition: evaluation of inhalation devices and absorption mechanisms. Thesis, Faculty of Pharmacy, University of Uppsala. Sweden; 1993. p 1-78.
6. Snell NJ, Ganderton D. Assessing lung deposition of inhaled medications: consensus statement from a workshop of the British Association for Lung Research, held at the Institute of Biology, London, UK on 17 April, 1998. Respir Med 1999;93:123-133.
7. Foe K, Cutler DJ, Brown KF, Seale JP. Metabolism kinetics of beclomethasone propionate esters in human lung homogenates. Pharm Res 2000;17:1007-1012.
8. Daley-Yates PT, Price AC, Sisson JR, Pereira A, Dallow N. Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal, and inhaled administration in man. Br J Clin Pharmacol 2001;51:400-409.
9. Würthwein G, Rohdewald P. Activation of beclomethasone dipropionate by hydrolysis to beclomethasone-17-monopropionate. Biopharm Drug Dispos 1990;11:381-394.
10. Harrison LI, Kurup S, Chen LZ, Cai JJ, Ekholm BP, Senta TA, Wighton TG, Shapiro GG. Pharmacokinetics of beclomethasone dipropionate (BDP) and metabolites from CFC-free BDP pressurized metered-dose inhalers in children. Eur Respir J [Suppl] 1998;12:436 [abstract].
11. Leach CL. Improved delivery of inhaled steroids to the large and small airways. Respir Med 1998;92:3-8.
12. Soria I, Harrison LI, Machacek JH, Chang SF, Cline AC, Stampone PA. Beclomethasone relative availability of oral versus inhaled beclomethasone dipropionate from an HFA-134A metered dose inhaler. Biopharm Drug Dispos 1998;19:297-302.
13. Newman S, Morén F, Pavia D, Little F, Clarke SW. Deposition of pressurized suspension aerosols inhaled through extension devices. Am Rev Respir Dis 1981;124:317-320.
14. Newman S. A comparison of lung deposition patterns between different asthma inhalers. J Aerosol Med 1995;8:21-27.
15. Pedersen S, Steffensen G, Ekman I, Tönnesson M, Borgå O. Pharmacokinetics of budesonide in children with asthma. Eur J Clin Pharmacol 1987;31:579-582.
16. 99mTc-labelled HFA-BDP inhaled via Autohaler™ in children. Eur Respir J 2000;16:540 [abstract].
17. Olsson B. Can in vitro measurements predict the lung deposition of dry-powder inhalers? J Aerosol Med 1997;10:13-16.
18. Devadason SG, Everard ML, MacEarlan C, Roller C, Summers QA, Swift P, Borgstrm L, Le Souëf PN. Lung deposition from the Turbuhaler in children with cystic fibrosis. Eur Respir J 1997;10:2023-2028.
19. Barnes PJ, Pedersen S, Busse W. Efficacy and safety of inhaled corticosteroids: new developments. Am J Respir Crit Care Med 1998;157:1-53.
20. Daley-Yates PT, Price AC, Pereira A, Richards DH. Absolute bioavailability of beclomethasone dipropionate (BDP) administered via the inhaled, intranasal and oral route in man. Eur Respir J [Suppl] 2000;16:280 [abstract].
21. Doull IJ, Freezer NJ, Holgate S. Growth of prepubertal children with mild asthma treated with inhaled beclomethasone dipropionate. Am J Respir Crit Care Med 1995;151:1715-1719.
22. Verberne AAPH. Frost C, Roorda RJ, van der Laag H, Kerrebijn K. One year treatment with salmeterol, compared with beclomethasone in children with asthma. Am J Respir Crit Care Med 1997;156:688-695.
23. Simons FE. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. N Engl J Med 1997;337:1659-1665.
24. Tinkelman DG, Reed CE, Nelson HS, Offord KP. Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children. Pediatrics 1993;92:64-77.